Reasons To Use HydroTrim® Water Soluble For The Treatment Of Bacterial Infections In Pigs

reading time
Article | 22.03.2024
Ulrich Klein

HydroTrim® is a new product from Huvepharma containing both sulfadiazine (500 mg/g) and nanonised trimethoprim (100 mg/g). The nanonisation enables trimethoprim to stay in suspension, even at high concentrated stock solutions of medicated water.

Sulfonamides and sulfonamide/trimethoprim combinations are among the most frequently used antibiotics in veterinary medicine. These drugs are used to treat a variety of bacteria, protozoal and certain fungal infections. They are most effective in the early stages of infections when pathogens multiply rapidly. 

 

Chemistry and mode of action

Sulfonamides are derivatives of sulfanilamides and are synthetically manufactured. Various sulfonamide products are therapeutically used in veterinary medicine with structural differences (sulfadiazine, sulfamethoxazole, sulfamethazine, others). 

Sulfonamides interfere with the biosynthesis of folic acid in bacterial cells by preventing para-aminobenzoic acid (PABA) from incorporating into the folic acid molecule.

Diaminopyrimidines (trimethoprim and others) also interfere with the biosynthesis of folic acid in bacterial cells. They prevent the conversion of dihydrofolic acid and tetrahydrofolic acid by competitive binding.

 

Figure 1. Mode of action of sulfonamides and trimethoprim

 

Sulfonamide and trimethoprim combinations act by targeting two sequential steps in the biosynthesis pathway for tetrahydrofolate (THF) as shown in Figure 1. The combined activity results in synergistic effects and increasing efficacy against different bacterial pathogens.

All sulfonamides have the same mechanism of action. Nevertheless, there are differences with respect to activity and pharmacokinetic behaviour at therapeutic concentrations. 

 

Sulfonamide and trimethoprim - therapeutic use in pigs

The European Medicines Agency (EMA) has categorised antibiotics for their practical use in animals. Sulfonamides and trimethoprim are considered as first line treatment options (Category D) and should be used for therapeutic purposes whenever possible.

The potentiating effect of sulfonamide / trimethoprim combinations is an important product advantage and can be used in different respects:

  1. to increase the efficacy of sulfonamides from bacteriostatic to bactericidal drugs
  2. to use the synergistic effect for treatment of low susceptible and/or resistant bacteria
  3. to reduce the incidence of resistance
  4. to broaden the antibacterial spectrum

 

Susceptibility of swine bacteria to sulfonamide / trimethoprim combinations

Susceptibility patterns of swine bacteria pathogens are ideally monitored over longer time periods to identify declines and changes in their sensitivity. In the Pan-European VetPath survey, the susceptibility against sulfamethoxazole/trimethoprim as a sulfonamide/trimethoprim representative was tested (Table 1). 

 

Table 1. Sulfamethoxazole / trimethoprim susceptibility of swine pathogens (VetPath survey)

 

Over a period of 12 years, similar susceptibilities were determined with no trend in minimum inhibitory concentration (MIC) changes. High susceptibilities were determined in the case of tested respiratory pathogens (A. pleuropneumoniaeP. multocidaS. suis). Low susceptibility was identified for Escherichia coli strains. The bacteria strains originated from eight different European countries.

The stable susceptibility of many bacteria species is one of the reasons for the high efficacy of sulfonamide/trimethoprim combination products in cases of treatment for a variety of bacterial infections in pigs. Their potent synergistic action prevents MIC increases long-term and the development of resistance.

 

Sulfonamides/trimethoprim - pharmacokinetics in pigs

Several pharmacokinetic studies in pigs have verified differences in the pharmacokinetic behaviour of sulfonamide/trimethoprim products at therapeutic concentrations. 

 

Table 2. Sulfonamide / trimethoprim pharmacokinetics in pigs

 

Sulfadiazine shows a longer elimination half-life which results in slower disappearance and higher and longer systemic availability in the target tissues in comparison to sulfamethoxazole. The higher distribution volume of the sulfadiazine/trimethoprim combination results in more intensive distribution into extravascular tissues in comparison to the sulfamethoxazole/trimethoprim product.

 

Cornerstone of therapeutic use of HydroTrim and potentiated sulfonamides

  • Potentiated sulfonamide products should be used as a first line treatment option to minimise the use of antimicrobials which are critically important in human medicine (quinolones; 3rd and 4th generation cephalosporines; polymyxins).
  • The synergistic interaction of sulfonamides with trimethoprim potentiates their clinical efficacy and exhibits bactericidal activity against many bacterial pathogens.
  • Pan-European MIC data confirms the consistent susceptibility of a variety of pig bacterial pathogens against potentiated sulfonamide products.
  • Pharmacokinetic properties are in favour of HydroTrim sulfadiazine/trimethoprim. This justifies the therapeutic use of HydroTrim as first preference in pig farms vs. other sulfonamide/trimethoprim combinations.
 

 

References are available on request.
global presence

Local support from a global company

Huvepharma® has a distribution network which covers more than 90 countries in 6 continents. Find your nearest Huvepharma® representative today.
Find your local contact
about us

Huvepharma®

Huvepharma® is a fast-growing, global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health and nutrition products.
more about us

Change country

The Huvepharma® distribution network covers 90 countries in 6 continents. Please select a country from the list below to see the products and services available in that region.

To view all products and services, select Global from the dropdown menu or click .

Africa

Asia

Europe

North America

Oceania

South America

Change language

Huvepharma has a remarkable distribution network which covers 90 countries in 6 continents. To offer you the best services, we ask you to select your country.

Europe

top
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now